semaglutide gi obstruction lawsuit in michigan digestive blockage class action gastrointestinal Subocclusive ileus following off-label high-dose semaglutide use in: Endocrinology, Diabetes & Metabolism Case Reports Volume 2025 Issue 4 (2025) filed against semaglutide gi obstruction attorney in

doi: 10.1111/jcmm.17985

They may recommend pausing at your current dose, delaying the next escalation, or exploring alternative medicationssuch as compounded tirzepatide or a different GLP-1 formulationthat may carry different side effect profiles for your individual case

The GLP-1 agonist, exenatide, increased fasting EF via endothelial nitric oxide (NO) synthase (eNOS) activation, nitric oxide (NO) production in endothelial cells, induced dose-dependent vasorelaxation, and reduced high-glucose or lipid-induced endothelial dysfunction in arterioles ex vivo [64]

For patients whose body aches stem from rapid metabolic shifts, the Microdose GLP-1 Protocol ($129/mo flat) offers a gentler entry point with the option to escalate as tolerance improves